On the first trading day of June, the Hong Kong Stock Connect innovative pharmaceutical sector experienced a sharp reversal, rising initially before plummeting in the afternoon session.
The Huabao Hang Seng Hong Kong Stock Connect Innovative Drug Selection Trading Open Ended Index Securities Inves (520880), which focuses 100% on innovative drug R&D, opened higher and surged nearly 3% before rapidly retreating. The decline accelerated in the afternoon, with the ETF closing down 1.61%, erasing its earlier gains above the 10-day moving average and recording an intraday swing of 5.75%.
Constituent stocks saw massive volatility, with 11 stocks experiencing intraday swings exceeding 10%. The core heavyweight, Akeso (09926), led the pack with a 16.43% swing—soaring over 10% at the open before closing down 1.86%, with a record-high turnover of HK$7.04 billion.
The backdrop included the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting held from May 29 to June 2. Akeso presented over 40 clinical research findings, with its internally developed, first-in-class PD-1/VEGF bispecific antibody, ivonescimab, showing excellent overall survival data in the HARMONi-6 study, reducing the risk of death by 34% in patients with squamous non-small cell lung cancer.
Despite this significant positive catalyst, why did the sector suddenly reverse course? Analysis suggests it was likely a combination of profit-taking after the news was priced in (deteriorating micro-trading structure) and short-term sentiment driven by rumors concerning US-China bilateral regulatory scrutiny.
From a trading perspective, June 1st marked the fourth day of the ASCO conference, by which time key data had largely been disclosed. Event-driven capital chose to take profits after the catalyst materialized, adhering to the "buy the rumor, sell the news" playbook. The current market is characterized by存量 funds博弈, and the lack of incremental capital, coupled with the fast-paced trading of short-term money, has exacerbated sector volatility.
Furthermore, several market rumors may have dampened bullish sentiment. Reports indicated that the US House of Representatives called for restrictions on investments in Chinese biotechnology, specifically naming a potential $15.2 billion collaboration between Hengrui and Bristol Myers Squibb. Concurrently, rumors circulated domestically about potential controls on the export of certain biopharmaceutical technologies. Additionally, Junshi Biosciences received an inquiry letter from the Shanghai Stock Exchange regarding its 42% sales expense ratio, signaling increased regulatory scrutiny.
How should investors view this major volatility? Institutions believe the current turbulence stems more from a short-term confluence of "catalyst realization, sentiment disturbance, and capital rotation" at the trading level, rather than a reversal of the industry's long-term fundamentals. Short-term fluctuations may, in fact, provide a more comfortable entry point for long-term positioning.
Analysis points out that recent market rumors have been debunked, with no fundamental negatives actually impacting the innovative drug sector. The combination of政策支持, valuations near底部, strong出海 momentum, and an approaching业绩拐点 suggests staying the course despite near-term volatility. Another report highlighted that the exceptional OS data for Akeso's ivonescimab significantly boosts the certainty of tapping into the global multi-billion dollar immuno-oncology and ADC market, reinforcing a bullish outlook on the sector's beta.
Strategically, it is advisable to avoid the high volatility stemming from sentiment-driven trades in the short term. From a medium-to-long-term perspective, the global competitiveness of China's innovative pharmaceutical industry remains intact. Investors may consider using ETF tools to accumulate positions in leading platform companies with global business development capabilities and稀缺 core pipelines when market volatility subsides and sentiment reaches a trough.
For pure exposure to innovative drugs, the Huabao Hang Seng Hong Kong Stock Connect Innovative Drug Selection Trading Open Ended Index Securities Inves (520880) offers 100% allocation to innovative drug R&D companies. Its top ten holdings account for over 70% of the portfolio, highlighting its focus on leaders. With underlying assets listed in Hong Kong, it offers high elasticity and supports T+0 trading.
For investors seeking to lower volatility, the场内唯一 Pharmaceutical ETF Huabao (562050) provides a unique allocation of "70% innovative drugs + 30% traditional Chinese medicine," a稀缺 combination in the market that blends the high growth potential of innovative drugs with the high dividend appeal of traditional Chinese medicine stocks.
Data is sourced from the Shanghai, Shenzhen, and Hong Kong stock exchanges, China Securities Index Co., Ltd., and Hang Seng Indexes Company. Institutional views are referenced from relevant research reports dated May 29 and May 31, 2026.
Note: The ETF does not charge a sales service fee. When subscribing for or redeeming fund units, the subscription/redemption agent may charge a commission of up to 0.5%, which includes related fees charged by the stock exchange and registration institutions. For detailed fund fee schedules, please refer to the respective fund's legal documents.
Risk Disclosure: The index constituents mentioned are for illustrative purposes only. Descriptions of individual stocks do not constitute investment advice in any form nor do they represent the holdings or trading动向 of any fund managed by the asset manager. The risk rating for the Pharmaceutical ETF Huabao and its feeder funds, as assessed by the fund manager, is R3-Medium Risk, suitable for Balanced (C3) and above investors. The risk rating for the Huabao Hang Seng Hong Kong Stock Connect Innovative Drug Selection Trading Open Ended Index Securities Inves and its feeder funds is R4-Medium to High Risk, suitable for Aggressive (C4) and above investors. Any information appearing in this article is for reference only. Investors are solely responsible for their independent investment decisions. Furthermore, any views, analysis, or forecasts herein do not constitute investment advice of any kind to the reader, and no liability is accepted for any direct or间接 losses arising from the use of this content. The performance of other funds managed by the fund manager does not guarantee the performance of this fund. Past performance of a fund is not indicative of its future results. Fund investment carries risks.
MACD golden cross signals have formed, and these stocks are performing well.
Comments